421 related articles for article (PubMed ID: 25263320)
1. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
[TBL] [Abstract][Full Text] [Related]
3. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S; Itzykson R; Seegers V; Raffoux E; Quesnel B; Chait Y; Sorin L; Dreyfus F; Cluzeau T; Delaunay J; Sanhes L; Eclache V; Dartigeas C; Turlure P; Harel S; Salanoubat C; Kiladjian JJ; Fenaux P; Adès L;
Blood; 2010 Nov; 116(19):3735-42. PubMed ID: 20664061
[TBL] [Abstract][Full Text] [Related]
4. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; O'Brien S; Fullmer A; Cortes JE; Wierda W; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):131-8. PubMed ID: 23260600
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
8. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
[TBL] [Abstract][Full Text] [Related]
9. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
10. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP
Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156
[TBL] [Abstract][Full Text] [Related]
11. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Jabbour E; Garcia-Manero G; Batty N; Shan J; O'Brien S; Cortes J; Ravandi F; Issa JP; Kantarjian H
Cancer; 2010 Aug; 116(16):3830-4. PubMed ID: 20564137
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
Saga T; Kanagawa M; Harada T; Lang L; Yamawaki F; Ishihara T
Intern Med; 2024 Mar; 63(6):781-790. PubMed ID: 37495538
[TBL] [Abstract][Full Text] [Related]
15. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
[TBL] [Abstract][Full Text] [Related]
16. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS
Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375
[TBL] [Abstract][Full Text] [Related]
17. Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Woo J; Deeg HJ; Storer B; Yeung C; Fang M; Mielcarek M; Scott BL
Biol Blood Marrow Transplant; 2017 Jan; 23(1):176-179. PubMed ID: 27789363
[TBL] [Abstract][Full Text] [Related]
18. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Jabbour E; Garcia-Manero G; Cornelison AM; Cortes JE; Ravandi F; Daver N; Kadia T; Teng A; Kantarjian H
Leuk Lymphoma; 2015 Feb; 56(2):390-4. PubMed ID: 24844364
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
20. Decitabine: in myelodysplastic syndromes.
McKeage K; Croom KF
Drugs; 2006; 66(7):951-8. PubMed ID: 16740014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
